Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
22.77
-1.56 (-6.41%)
At close: Nov 20, 2025, 4:00 PM EST
22.80
+0.03 (0.13%)
After-hours: Nov 20, 2025, 4:10 PM EST
Pacira BioSciences Revenue
Pacira BioSciences had revenue of $179.52M in the quarter ending September 30, 2025, with 6.49% growth. This brings the company's revenue in the last twelve months to $716.79M, up 3.14% year-over-year. In the year 2024, Pacira BioSciences had annual revenue of $700.97M with 3.85% growth.
Revenue (ttm)
$716.79M
Revenue Growth
+3.14%
P/S Ratio
1.45
Revenue / Employee
$907,330
Employees
790
Market Cap
979.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 700.97M | 25.99M | 3.85% |
| Dec 31, 2023 | 674.98M | 8.16M | 1.22% |
| Dec 31, 2022 | 666.82M | 125.29M | 23.14% |
| Dec 31, 2021 | 541.53M | 111.89M | 26.04% |
| Dec 31, 2020 | 429.65M | 8.62M | 2.05% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PCRX News
- 9 days ago - Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences - GlobeNewsWire
- 9 days ago - DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business - PRNewsWire
- 13 days ago - Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance - GlobeNewsWire
- 15 days ago - Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee - GlobeNewsWire
- 16 days ago - Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control - GlobeNewsWire
- 21 days ago - Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025 - GlobeNewsWire
- 24 days ago - Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL® - GlobeNewsWire